OncLive TV

Alice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).

Lawrence D. Kaplan, MD, discusses research with bispecific monoclonal antibodies in follicular lymphoma.

Jonathan E. Rosenberg, MD, discusses the phase 3 KEYNOTE-045 trial in advanced urothelial cancer.

Brandon G. Smaglo, MD, FACP, discusses the role of immunotherapy in advanced gastric cancer.

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Panayiotis S. Savvides, MD, discusses COVID-19 precautions for patients with lung cancer.

Ivy P. Altomare, MD, discusses investigational agents in immune thrombocytopenia.

Jerald P. Radich, MD, discusses measuring minimal residual disease (MRD) in hematologic malignancies.

Nitika Thawani, MD, discusses identifying the difference between adverse events that are associated with radiation versus COVID-19 symptoms in lung cancer.

Preetesh Jain, MD, PhD, discusses the next steps for a study examining the efficacy of venetoclax in high risk relapsed mantle cell lymphoma.

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

Anastasios (Tassos) Dimou, MD, shares advice from managing patients with non–small cell lung cancer who experience disease progression following therapy.

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

David D. Thiel, MD, chair, discusses the measures that are being taken to protect patients and providers from the coronavirus disease 2019 (COVID-19).

Mario Sznol, MD, discusses the use of immunotherapy in melanoma.

Hope S. Rugo, MD, discusses the results of the phase 3 KEYNOTE-522 trial in triple-negative breast cancer (TNBC).

Sonali M. Smith, MD, discusses unmet clinical needs in indolent lymphomas.

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

Douglas A. Nelson, MD, discusses why patients with metastatic colorectal cancer are often referred to surgeons before medical oncologists.

Neehar Parikh, MD, discusses the role of radiation in hepatocellular carcinoma (HCC).

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

Sharyn Lewin, MD, FACS, discusses the impact of the coronavirus disease 2019 (COVID-19) on cancer care.

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.